Immunosuppressants, Organ Transplants, and Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis
|
|
- Collin Wilkinson
- 5 years ago
- Views:
Transcription
1 Immunosuppressants, Organ Transplants, and Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis Introduction This report examines treatment protocols evolved over the last ten years. It also appraises novel compounds in development, highlighting potential clinical advances along with analysis of the potential impact of regenerative medicine (stem cells) on the market, with drivers and resistors to market growth. Scope Ten-year forecasts of the number of organ donors, transplants and maintenance populations by organ and country. Review of the regenerative medicine market, including estimates of the market size, analysis of over 200 clinical trials & focus on potential applications. In-depth analysis of late-stage pipeline products, with discussion of potential clinical advances and how they address current unmet needs. Overview of organ donation trends, e.g., maximum theoretical supply, impact of initiatives to increase donors, and impact of changing donor demographics. Analysis of US treatment protocols at discharge by drug class and review of graft survival rates by organ, including causes of graft loss. Research and analysis highlights Cellular-based therapies, which have the potential to induce graft tolerance, represent a major disruptive technology which could potentially replace, or reduce, the use of primary immunosuppressants. Modern immunosuppressive protocols have resulted in improvement in short-term graft survival rates and the focus is now shifting towards improving long-term graft survival, although achieving this goal will be challenging A distant goal of regenerative medicine is to develop bioengineered organs and tissues, although the replacement of whole kidneys, hearts or livers is not yet clinically feasible and the development of spatially complex organs will require many advances in tissue engineering Key reasons to purchase this research Understand the driving forces in the transplantation market Evaluate current market dynamics & learn which novel products offer the greatest potential clinical advances over the next several years and why Assess your competitive position vis-à-vis other companies Understand which market areas offer the greatest potential growth prospects Develop strategies to optimize your transplantation portfolio and identify new areas for market entry
2 Table of Contents Shaun Falkingbridge 2 Disclaimer 2 Executive summary 10 Market environment 10 Solid organ transplants 11 Regenerative medicine 11 Pipeline analysis 12 Chapter 1 Market environment 14 Summary 14 Background 15 Immunosuppression 15 Types of rejection 15 Immunosuppressive therapy 16 Blood group compatibility 18 Tapering of immunosuppression 18 Market valuation 18 Prograf 19 Background 19 Impact of new formulation and generics 19 Conclusion 21 Neoral 22 Background 22 Impact of tacrolimus and generics 22 Conclusion 23 CellCept 23 Background 23 Impact of generics 24 Other brands 24 Evolution in therapeutic protocols 25 Calcineurin inhibitors 26 Shift from ciclosporin to tacrolimus 26 Safety and efficacy 27 Side effects 27 Conclusion 28 Adjunctive agents 28 mtor inhibitors 30 Enhancing long-term graft survival 30 Sirolimus 30 CNI avoidance 30 Combination use 30 Early/late CNI conversion 30 Everolimus 31 Side effects 32
3 Conclusion 32 Induction therapies 33 Trends in graft-survival rates 35 Incremental/steady improvements in survival 35 Factors affecting survival rates 37 Non-related patient death 37 Immunosuppressants increase cardiovascular risk factors 38 Cancer 39 Acute rejection 39 Interstitial fibrosis/tubular atrophy 39 CNI nephrotoxicity 41 Glomerular disease 41 Delayed graft function 41 Non-adherence 42 Conclusion 42 Future outlook 43 Chapter 2 Solid organ transplants 45 Summary 45 Introduction 46 Trends in organ donation 47 Regional trends 47 Cause of death 50 Donor legislation 51 Religious factors 52 Number of transplants 52 Organ gap 53 Indications for transplants 54 Kidney 54 Liver 56 Heart 57 Increasing donor supply 57 Maximum theoretical number of donors 57 Strategies to increase the number of donors 57 Spain: active detection 58 The UK: establishment of the Organ Donation Taskforce 58 The US: the Organ Donation Breakthrough Collaborative 60 Forecast number of transplants/functioning grafts 61 Future outlook 65 Chapter 3 Regenerative medicine 66 Summary 66 Introduction 67 Types of cellular therapies 67 Embryonic stem cells 68 Adult stem cells 70 Fully differentiated cells 71 Organ augmentation and replacement 71
4 Clinical application of cellular therapies 73 Introduction 73 Cardiovascular disease 75 Bone marrow mononuclear cells 75 Endothelial progenitor cells 75 Mesenchymal stem cells 76 Stem cells and heart transplantation 76 Outlook 76 Kidney disease 77 Kidney repair and regeneration 77 Mesenchymal stem cells and transplantation 77 Mesenchymal stem cells and chronic/acute kidney disease 79 Development of whole organs 80 Outlook 81 Liver disease 81 Stem cells and treatment of cirrhosis 81 Hepatocyte transplantation 82 Stem cells and transplantation 82 Regenerative medicine market 82 Market value 82 Autologous chondrocyte implantation 83 Skin-substitutes 84 Apligraf 84 Dermagraft 85 Regulation of cellular therapies 86 US 86 EU 87 Japan 87 China 88 Future outlook 89 Chapter 4 Pipeline analysis 90 Summary 90 Introduction 91 Bristol-Myers Squibb 91 Belatacept 91 Astellas 93 Alefacept 93 ASKP-1240 (4D11) 94 ASP-015K 94 Novartis 95 Sotrastaurin 95 Pfizer 96 Tasocitinib 96 Isotechnika 96 Voclosporin 96 Other companies 96
5 Novel immunosuppressive agents impact on the market 97 Business models in cell therapy 100 Key success factors 100 Manufacturing process 101 Acute versus elective indications 101 Risk of product substitution 102 Estimates revenues for Prochymal in transplantation 103 Future outlook 104 Appendix 105 Primary research methodology 105 IMS sales data 105 Transplant data 106 Glossary 107 Bibliography 109 Table of figures Figure 1: Market share of Advagraf, Prograf and Neoral, Spain, Figure 2: Ciclosporin and tacrolimus use in US kidney transplants prior to discharge, Figure 3: Adjunctive agents used in US kidney transplant patients prior to discharge, Figure 4: Sirolimus use in US kidney transplant patients between discharge and one year following transplantation, Figure 5: Induction therapy use in US kidney transplants recipients, Figure 6: Graft survival at one, five and ten years, deceased donor kidney transplants, US 36 Figure 7: Graft survival at one, five and ten years, deceased donor liver transplants, US 37 Figure 8: Graft survival at one, five and ten years, heart transplants, US 38 Figure 9: Reasons for loss of kidney grafts 40 Figure 10: Age of deceased donor kidney recipients (non-ecd), Figure 11: Number of donors by type in the 7MM, Figure 12: Organ donation rates per million population by donor type, Figure 13: Living donation rates per million population, Figure 14: Kidney waiting list and kidney transplants, US, Figure 15: Indications for kidney transplant, US, Figure 16: Indications for liver transplant, US, Figure 17: Number of deceased donors by type, UK, Figure 18: Number of transplants and organ donors, Figure 19: Types of cellular therapies 68 Figure 20: Number of clinical trials by stem cell type, Figure 21: Drivers and resistors to regenerative medicine 88 Figure 22: The challenges of developing immunosuppressants 94 Figure 23: Comparison of uptake of Prograf and CellCept US kidney transplants, Figure 24: Drivers and resistors for primary immunosuppressants 99
6 Table of tables Table 1: Types of immunosuppressants 17 Table 2: Immunosuppressants sales ($m) in the 7MMs, by class and brand, Table 3: Current access of donor supply by country 58 Table 4: Number of transplants and organ donors, Table 5: Prevalence of functioning grafts, by country and organ, Table 6: Selected stem cell clinical trials 78 Table 7: Examples of approved cell-based therapies 85
Organ Transplantation Market Research Report- Global Forecast Till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481
Immunosuppressive e therapy for kidney transplant in adults Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 NICE 2018. All rights reserved. Subject to Notice of rights
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482
Immunosuppressive e therapy for kidney transplant in children and young people Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482 NICE 2018. All rights reserved. Subject
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationTransplant Overview. Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005
Transplant Overview Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005 CTI Clinical Trial and Consulting Services Drug Development Company focused in key
More informationSickle-cell Anemia Therapeutics Market in the US
Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sector Publishing Intelligence Limited (SPi) has been marketing business and market
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationGastric Cancer. Introduction
Gastric Cancer Introduction Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies
More informationLUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC279DFR PUBLICATION DATE OCTOBER 2013 LUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND Executive Summary Table below presents the key metrics of Lupuzor for Systemic Lupus Erythematosus (SLE)
More informationREFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets
More informationREFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the
More informationAtopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research reports
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationDry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013
Dry Eye Syndrome - Current and Future Players GDHC1016FPR / Published May 2013 Executive Summary Significant growth is expected in the DES market from 2012-2022. GlobalData estimates 2012 DES therapeutic
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationREFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets
More informationREFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013
More informationHip & Knee Orthopedic Surgical Implants Market: Country wise Outlook
Global Hip & Knee Orthopedic Surgical Implants market is projected to reach more than US$ 12 Billion by 2021, at a CAGR of XX% from 2016 to 2021. The growing prevalence of symptomatic osteoarthritis and
More informationRe: Final Appraisal Determination - Immunosuppressive therapy for kidney transplant in adults (review of technology appraisal guidance 85)
January 19 th, 2016 Dr Margaret Helliwell Vice chair National Institute for Health and Care Excellence 10 Spring Gardens London SW1A 2BU Dear Margaret Re: Final Appraisal Determination - Immunosuppressive
More informationREFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Dupilumab in the nine major pharmaceutical markets
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationCurrent and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
More informationREFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif
More informationInnovation In Transplantation:
Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationREFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 BRODALUMAB (PSORIASIS) - Executive Summary Table below presents key metrics for brodalumab in seven of the nine major pharmaceutical markets covered
More informationREFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) Executive Summary Table below provides a summary of the key metrics for Cariprazine in the seven major pharmaceutical
More informationREFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India
More informationREFERENCE CODE GDHCER052 PUBLICAT ION DATE NOVEMBER 2013 DIABETIC NEPHROPATHY - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER052 PUBLICAT ION DATE NOVEMBER 2013 DIABETIC NEPHROPATHY - Executive Summary Diabetic nephropathy is one of the microvascular complications of diabetes, along with diabetic neuropathy
More informationREFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - India Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in India 2012 We estimate the 2012 PsO drug
More informationREFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012
More informationREFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
More informationREFERENCE CODE GDHC319DFR PUBLICAT ION DATE DECEMBER 2013 EYLEA (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC319DFR PUBLICAT ION DATE DECEMBER 2013 EYLEA Executive Summary The table below presents a summary of the key metrics for Eylea (Microvascular Complications for Diabetes) for recombinant
More informationSpondyloarthropathies: Disease Perception Limits Market
Spondyloarthropathies: Disease Perception Limits Market Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form
More informationREFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG Executive Summary Sales for Chronic Heart Failure in the Japan The Japan Chronic heart failure (CHF) therapeutics
More informationDry Eye Syndrome. US Drug Forecast and Market Analysis to GDHC1115CFR / Published May 2013
Dry Eye Syndrome US Drug Forecast and Market Analysis to 2022 GDHC1115CFR / Published May 2013 Executive Summary Sales for Dry Eye Syndrome in the US The Dry Eye Syndrome (DES) market in the US will grow
More informationREFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m
More informationGlobal Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts ( ) September 2016
Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts (2016-2020) September 2016 Global CINV Market Report Scope of the Report The report titled Global Chemotherapy Induced
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationGlobal Irritable Bowel Syndrome (IBS) Market: Trends & Opportunities ( )
Global Irritable Bowel Syndrome (IBS) Market: Trends & Opportunities (2012-17) Scope of the Report The report titled Global Irritable Bowel Syndrome Market: Trends and Opportunities (2012-17) provides
More informationBRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationREFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS Executive Summary Sales for Atopic Dermatitis 2012 in US The US Atopic dermatitis market was worth approximately $1.35 billion
More information2017 CST-Astellas Canadian Transplant Fellows Symposium
2017 CST-Astellas Canadian Transplant Fellows Symposium The Future of Transplantation Atul Humar, MD Atul Humar is a Professor in the Department of Medicine, University of Toronto. Dr. Humar received his
More informationPharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research
More informationREFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India
More informationPrecision Medicine and not Individualized Therapy is Required for Successful Novel Drug Development
Precision Medicine and not Individualized Therapy is Required for Successful Novel Drug Development 1 Disclosures F Vincenti University of California San Francisco, San Francisco, United States I have
More informationREFERENCE CODE GDHC321DFR PUBLICAT ION DATE DECEMBER 2013 ATRASENTAN (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC321DFR PUBLICAT ION DATE DECEMBER 2013 Executive Summary The table below presents a summary of the key metrics for Atrasentan (Microvascular Complications for Diabetes) in the seven
More informationMyfortic Transplant Coordinator Survey: Defining the perceptions of generic mycophenolate mofetil
Myfortic Transplant Coordinator Survey: Defining the perceptions of generic mycophenolate mofetil July 28, 2010 Prepared for: Steve Arcona, PhD Director, Outcomes Research Novartis Pharmaceuticals Corporation
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationREFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - Executive Summary The table below summarizes the key metrics for Safinamide in the 8MM Parkinson s disease (PD)
More informationCyclokat (Dry Eye Syndrome)
Cyclokat (Dry Eye Syndrome) Forecast and Market Analysis to 2022 GDHC191DFR / Published July 2013 Executive Summary Below table provides a summary of the key metrics for Cyclokat in the major pharmaceuticals
More informationREFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Stalevo/Comtan in the 8MM Parkinson
More informationREFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for cariprazine in the Major Depressive Disorder (MDD)
More informationREFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) Executive Summary The table below presents the key metrics for Mavrilimumab in the 10MM Rheumatoid Arthritis
More informationREFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for brexpiprazole in the Major Depressive Disorder
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationA Rare Opportunity in Transplant.
A Rare Opportunity in Transplant. ENV-18-104.0 1 Forward Looking Statements Certain information in this presentation may constitute forward-looking information within the meaning of applicable securities
More informationREFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - Executive Summary Human PapillomaVirus (HPV) Vaccine Sales Expected to Grow Modestly During the Forecast
More informationREFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - Executive Summary Meningococcal Vaccines: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Epidemiology Targeted
More informationREFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Duodopa in the 8MM Parkinson s Disease
More information1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Diabetic Foot Ulcer Therapeutics - Introduction 2.1 Overview Diabetic Foot Ulcer
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Diabetic Foot Ulcer Therapeutics - Introduction 2.1 Overview 2.1.1 Diabetic Foot Ulcer Classification Systems 2.2 Epidemiology 2.2.1 Historic
More informationREFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA Executive Summary Schizophrenia Sales in the US, 2012 The combined sales of medications carrying an indication in schizophrenia in
More informationGlobal Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage
Global Influenza Drugs and Vaccines Market By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent): Analysis By Region, By Country: Opportunities and Forecast (2016-2021)
More informationDental Bone Graft Market Research Report - Forecast to 2027
Report Information More information from: https://www.marketresearchfuture.com/reports/867 Dental Bone Graft Market Research Report - Forecast to 2027 Report / Search Code: MRFR/DM/0365-HCRR Publish Date:
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationPharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market
More informationCancer in kidney transplant recipients: epidemiology and prevention
BTS 2018, Brighton Cancer in kidney transplant recipients: epidemiology and prevention Adnan Sharif Queen Elizabeth Hospital Birmingham Outline 1. The burden of cancer after kidney transplantation 2. Epidemiology
More informationREFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of AstraZeneca/Ardelyx s tenapanor for Irritable
More informationU.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon),
U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin,
More informationREFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Nouriast in the 8MM Parkinson s Disease
More informationTABLE 4 U.S. TEETH CLEANING VISITS BY SELECTED CHARACTERISTICS (%) TABLE 4 (CONTINUED) FIGURE 2 U.S. POPULATION WITH TEETH CLEANING
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 METHODOLOGY... 2 ANALYST... 3 RELATED BCC STUDIES... 3 BCC ONLINE SERVICES... 3 DISCLAIMER...
More informationREFERENCE CODE GDME0188M AR PUBLICATION DATE FEBRUARY 2014 BIOPSY DEVICES - GLOBAL ANALYSIS AND MARKET FORECASTS
REFERENCE CODE GDME0188M AR PUBLICATION DATE FEBRUARY 2014 BIOPSY DEVICES - Executive Summary The table below provides an overview of the global biopsy devices market during the forecast period from 2013
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationREFERENCE CODE GDHC1042FPR PUBLICAT ION DATE DECEMBER 2014 IRRITABLE BOWEL SYNDROME CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1042FPR PUBLICAT ION DATE DECEMBER 2014 IRRITABLE BOWEL SYNDROME Executive Summary Sales of Irritable Bowel Syndrome Market The Irritable Bowel Syndrome (IBS) market in the 7MM (US,
More informationREFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Furiex (Actavis) s eluxadoline for Irritable
More informationREFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - Executive Summary Below table provides a summary of Belviq for obesity in the nine major pharmaceutical markets during the forecast
More informationREFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Parkinson s Disease in Japan Market The Parkinson
More informationGlobal Dental Implant Market Research Report 2018
Report Information More information from: https://www.wiseguyreports.com/reports/3220035-global-dental-implant-market-research-report-2018 Global Dental Implant Market Research Report 2018 Report / Search
More informationGlobal Coverage. Regional Coverage. Country Coverage Company Coverage
Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) By Type- ALD and NAFLD ALD Stages - Alcoholic Steatosis
More informationREFERENCE CODE GDHC317DFR PUBLICAT ION DATE DECEMBER 2013 LUCENTIS (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC317DFR PUBLICAT ION DATE DECEMBER 2013 LUCENTIS Executive Summary The table below presents a summary of the key metrics for Lucentis (Microvascular Complications for Diabetes) for recombinant
More informationMexico Ostomy Drainage Bags Market Outlook to 2020
Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationDivya Jain Arwindekar, DO Transplant Nephrologist Advocate Christ Medical Center & Associates in Nephrology
Divya Jain Arwindekar, DO Transplant Nephrologist Advocate Christ Medical Center & Associates in Nephrology Not a cure to kidney disease, but it is a very effective treatment Patients still have chronic
More informationPediatric Kidney Transplantation
Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida
More informationGlobal Cosmetic Dentistry Market Research Report 2018
Report Information More information from: https://www.wiseguyreports.com/reports/3029111-global-cosmetic-dentistry-market-research-report- 2018 Global Cosmetic Dentistry Market Research Report 2018 Report
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationREFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Apokyn in the 8MM Parkinson s Disease
More informationSAMPLE. Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012
Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012 The Renal Cell Carcinoma (RCC) Disease Therapeutics Market GlobalData s analysis suggests
More informationREFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major
More informationPegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013
PegIntron (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1143DFR / Published May 2013 Executive Summary PegIntron (peginterferon alfa-2b) Key Metrics in the Major Pharmaceutical Markets 2012
More informationREFERENCE CODE GDHC482DFR PUBLICAT ION DATE OCTOBER 2014 EYLEA (MACULAR EDEMA AND MACULAR DEGENERATION) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC482DFR PUBLICAT ION DATE OCTOBER 2014 EYLEA (MACULAR EDEMA AND MACULAR DEGENERATION) - Executive Summary Table below presents the key metrics of Eylea for macular edema (ME) and age-related
More informationREFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationGlobal Standard Radiography Film X-Ray Film Printer Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Standard Radiography Film X-Ray Film Printer Market Research Report 2016 Global Standard Radiography Film
More information